Skip to content

Safety evaluation of long-term ingestion of D-allulose in borderline diabates and type 2 diabetes.

Safety evaluation of long-term ingestion of D-allulose in borderline diabates and type 2 diabetes. - Safety evaluation of long-term ingestion of D-allulose in borderline diabates and type 2 diabetes.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000036394
Enrollment
20
Registered
2019-04-03
Start date
2009-08-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline diabetes, type 2 diabetes

Interventions

Intake of test food for 12 consecutive weeks

Sponsors

Rare Sugar Foods LLC
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Individuals who sign the consent document 2)Adult males and females aged 20-75 years 3)Individuals who satisfy inclusion criteria as below. Borderline diabetes: Fasting blood glucose level is ranged from 110 mg/dL to 125 mg/dL Diabetes: Type 2 diabetes under drug treatment

Exclusion criteria

Exclusion criteria: (1)daily intake of dietary supplement related to blood glucose (2)serious damage to the liver, the renal, the heart, the lung, endocrine systems and metabolic functions (3)currently taking medications excluding diabetes patients (4)heavy user of alcohol and extremely random dietary habit (5)allergy to foods and medicines (6)abnormal values in the screening examination judged by the principal doctor (7)pregnancy, breastfeeding, or expected / planned pregnancy (8)participation in another clinical study (9)blood donation within 12 weeks of the screening examination (> 400 mL) or 4weeks (> 200 mL), or directed donation within 2 weeks of the screening examination (10)anyone judged as ineligible to participate in this study by the principal physician

Design outcomes

Primary

MeasureTime frame
Occurrence, types, magnitude and frequency of the adverse event(including clinical examinations)

Countries

Japan

Contacts

Public ContactNoriko Hayashi

Rare Sugar Foods LLC Matsutani Chemical Industry Co., Ltd.

noriko-hayashi@matsutani.co.jp072-771-2044

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026